Skip to Content

Molecular Pharmacology USA Ltd MLPH

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Molecular Pharmacology USA Ltd. is a development stage biotechnology company, through its subsidiary is engaged in the business of developing and commercializing a new analgesic and anti-inflammatory molecule known as Tripeptofen. Tripeptofen is likely to appear in a new group of products suitable for the treatment of common every-day pain. As an analgesic and anti-inflammatory drug, Tripeptofen is unusual due to its rapid speed of action and its topical or rub-on application. The majority of over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs. Geographically, the business presence of the firm is seen across the region of Australia and USA.

Contact
Drug Discovery Centre, 284 Oxford Street
Perth, WA, 6007
T +61 894433011
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2014
Fiscal Year End Jun 30, 2015
Stock Type Distressed
Employees